Skip to main content
Year archive

IMMUPHARMA PLC — 2020 filings

All 92 regulatory filings released by IMMUPHARMA PLC (IMM) in 2020, sourced directly from the official regulator.

92 Filings
2020 Period
2020 filings (92)
Filing Released Lang
IMM TO PRESENT AT BIOTECH SHOWCASE DIGITAL 2021
Regulatory Filings
2020-12-02 English
Total Share Capital Notification
Share Issue/Capital Change
2020-11-30 English
IMM - RNS - voting rights and denominator Euronext 30 Nov 2020 FINAL VERSION.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-11-30 English
Grant of Share Options & PDMR dealing
Remuneration Information
2020-11-26 English
Conversion of Convertible Security
Share Issue/Capital Change
2020-11-24 English
Conversion of Convertible Security
Capital/Financing Update
2020-11-23 English
Conversion of Convertible Security
Capital/Financing Update
2020-11-23 English
Update : FDA confirms 4 Dec for Type ‘A’ meeting
Legal Proceedings Report
2020-11-20 English
FDA confirms 4 December 2020 for Type ‘A’ meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients
Regulatory Filings
2020-11-20 English
Total Share Capital Notification - Replacement
Declaration of Voting Results & Voting Rights Announcements
2020-11-18 English
IMM - voting rights and denominator Euronext amended FINAL VERSION18 Nov 2020.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-11-18 English
Update on submission to the FDA
Legal Proceedings Report
2020-11-10 English
Update on submission to the FDA for the forthcoming international Phase 3 trial of Lupuzor™ in Lupus patients
Regulatory Filings
2020-11-10 English
Grant of Share Options & PDMR dealing
Director's Dealing
2020-10-26 English
Total Share Capital Notification
Declaration of Voting Results & Voting Rights Announcements
2020-09-30 English
Interim Results
Interim / Quarterly Report H1 2020
2020-09-30 English
IMM RNS Interim Results end June 2020 FINAL VERSION.pdf
Interim / Quarterly Report H1 2020
2020-09-30 English
IMM - voting rights and denominator Euronext 30 Sept 2020 FINAL VERSION.pdf
Share Issue/Capital Change
2020-09-30 English
Share Subscription into Incanthera plc
Share Issue/Capital Change
2020-09-29 English
Share Subscription into Incanthera plc
Capital/Financing Update
2020-09-29 English
Repayment of Convertible Security
Capital/Financing Update
2020-09-22 English
Repayment of Convertible Security
Capital/Financing Update
2020-09-22 English
Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients
Legal Proceedings Report
2020-09-11 English
Update on submission to the FDA
Legal Proceedings Report
2020-09-11 English
Conversion of Convertible Security
Share Issue/Capital Change
2020-09-10 English
Conversion of Convertible Security
Share Issue/Capital Change
2020-09-10 English
Conversion of Convertible Security
Share Issue/Capital Change
2020-09-09 English
Conversion of Convertible Security
Regulatory Filings
2020-09-09 English
Holding(s) in Company
Major Shareholding Notification
2020-09-08 English
Director/PDMR Shareholding / TR -1
Major Shareholding Notification
2020-09-08 English
Placing - update; related party transaction)
Regulatory Filings
2020-09-07 English
Placing to raise £6.5 million – update - related party transaction
Share Issue/Capital Change
2020-09-07 English
Conversion of Convertible Security
Regulatory Filings
2020-09-03 English
ImmuPharma - Conversion of Convertible Security
Share Issue/Capital Change
2020-09-03 English
Placing to raise £6.5 million
Regulatory Filings
2020-09-02 English
ImmuPharma - Placing to raise £6.5 million
Share Issue/Capital Change
2020-09-02 English
Holding(s) in Company
Major Shareholding Notification
2020-09-01 English
FDA submission for Special Protocol Assessment
Legal Proceedings Report
2020-07-27 English
Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients
Legal Proceedings Report
2020-07-27 English
2020 AGM – ALL RESOLUTIONS PASSED
AGM Information
2020-06-18 English
Total Share Capital Notification
Declaration of Voting Results & Voting Rights Announcements
2020-06-16 English
IMM-voting-rights-and-denominator-Euronext-16-June-FINAL-VERSION.pdf
Declaration of Voting Results & Voting Rights Announcements
2020-06-16 English
TR-1 Notification of major holdings
Director's Dealing
2020-06-11 English
STRAT. INVTS FROM 2 SPECIALIST US H'CARE INVESTORS
Share Issue/Capital Change
2020-06-11 English
STRATEGIC INVESTMENTS FROM TWO SPECIALIST US HEALTHCARE INVESTORS
Capital/Financing Update
2020-06-11 English
Change of Registered Office Address
Regulatory Filings
2020-06-05 English
Notification of Change of Registered Office Address
Regulatory Filings
2020-06-05 English
Notification of Change of AGM Venue
Regulatory Filings
2020-06-02 English
Notification of Change of AGM Venue
Regulatory Filings
2020-06-02 English
Notice of AGM and posting of Report & Accounts
Report Publication Announcement
2020-05-21 English
IMM Notice of AGM May 2020.pdf
AGM Information
2020-05-21 English
ImmuPharma Annual Report 31.12.2019 FINAL.pdf
Annual Report FY 2019
2020-05-21 English
IMM Blank Proxy for 18 June 2020 AGM.pdf
AGM Information
2020-05-21 English
IMM RNS Posting of RA and Notice of AGM May 2020.pdf
Report Publication Announcement
2020-05-21 English
TR-1: Notification of major holdings
Major Shareholding Notification
2020-05-18 English
Efforts in fight vs Covid-19 with Lupuzor; Ureka
Regulatory Filings
2020-05-14 English
ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka
Regulatory Filings
2020-05-14 English
ImmuPharma-PLC-FINAL-ACCOUNTS-End-Dec-2019.pdf
Annual Report FY 2019
2020-04-30 English
Audited Report & Accounts published on website
Regulatory Filings
2020-04-30 English
FINAL RESULTS FOR THE 12M ENDED 31/12/19
Earnings Release FY 2019
2020-04-30 English
IMM FINAL RESULTS END DEC 2019 _ 30 April 2020 FINAL VERSION (004).pdf
Earnings Release FY 2019
2020-04-30 English
IMM live on Investor Meet Company platform 7 April
Regulatory Filings
2020-04-06 English
Holding(s) in Company
Major Shareholding Notification
2020-04-03 English
Holding(s) in Company
Major Shareholding Notification
2020-04-02 English
Second Price Monitoring Extn
Regulatory Filings
2020-03-31 English
Price Monitoring Extension
Regulatory Filings
2020-03-31 English
Second Price Monitoring Extn
Regulatory Filings
2020-03-31 English
Price Monitoring Extension
Regulatory Filings
2020-03-31 English
£1.5m Subscrip'n to fund R&D pipeline- replacement
Regulatory Filings
2020-03-30 English
£1.5m Subscription to fund R&D pipeline expansion
Regulatory Filings
2020-03-30 English
Erratum - Subscription to raise £1.5 million to fund expansion of R&D pipeline
Share Issue/Capital Change
2020-03-30 English
Subscription to raise £1.5 million To fund expansion of R&D pipeline
Share Issue/Capital Change
2020-03-30 English
Second Price Monitoring Extn
Regulatory Filings
2020-03-20 English
Price Monitoring Extension
Regulatory Filings
2020-03-20 English
Second Price Monitoring Extn
Regulatory Filings
2020-03-18 English
Price Monitoring Extension
Regulatory Filings
2020-03-18 English
Second Price Monitoring Extn
Regulatory Filings
2020-03-16 English
Price Monitoring Extension
Regulatory Filings
2020-03-16 English
Price Monitoring Extension
Regulatory Filings
2020-03-04 English
Incanthera plc – Admission to trading on NEX
Regulatory Filings
2020-02-28 English
Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document
Share Issue/Capital Change
2020-02-28 English
Price Monitoring Extension
Regulatory Filings
2020-02-21 English
Incanthera announces Rule 23 Notice re NEX listing
Regulatory Filings
2020-02-17 English
Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market
Regulatory Filings
2020-02-17 English
Second Price Monitoring Extn
Regulatory Filings
2020-02-12 English
Price Monitoring Extension
Regulatory Filings
2020-02-12 English
Update on the Avion Agreement
M&A Activity
2020-02-06 English
ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor™'s new international Phase III trial
Regulatory Filings
2020-02-06 English
Second Price Monitoring Extn
Regulatory Filings
2020-02-05 English
Price Monitoring Extension
Regulatory Filings
2020-02-05 English
Second Price Monitoring Extn
Regulatory Filings
2020-01-07 English
Price Monitoring Extension
Regulatory Filings
2020-01-07 English